Analysis on the linkage of 415 generic medicines passing consistency evaluation and essential medicine list ， medical insurance list and centralized procurement list from the perspective of medicine accessibility
- VernacularTitle:药品可及性视角下415种过评仿制药与基药、医保、集采目录的联动情况分析
- Author:
Huan ZHANG
1
;
Nuo XU
2
;
Gan XU
3
;
Liping LIU
4
Author Information
1. Kangda College，Nanjing Medical University，Jiangsu Lianyungang 222000，China
2. Jiangsu Hansoh Pharmaceutical Group Co.，Ltd.，Jiangsu Lianyungang 222000，China
3. School of Management，Beijing University of Chinese Medicine，Beijing 100029，China
4. Dept. of Clinical Pharmacy，School of Pharma cy，Nanjing Medical University，Nanjing 211166，China
- Publication Type:Journal Article
- Keywords:
generic drugs;
consistency evaluation;
essential medicine list;
medical insurance list;
centralized procurement list
- From:
China Pharmacy
2022;33(6):661-665
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIV E To in vestigate the situation ，achievements and proble ms of consistency evaluation policy of generic medicines in China. METHODS The descriptive analysis was performed after collecting and sorting out the information of generic medicine passing consistency evaluation （GMPCE） published on the official website of the National Medical Products Administration. The basic information ，the distribution and changes of GMPCE were analyzed statistically in National Essential Medicine List （hereinafter refer to as “essential medicine list ”），Medicine List for National Basic Medical Insurance ，Industrial Injury Insurance and Maternity Insurance （hereinafter refer to as “medical insurance list ”）and the result of the successful selection of centralized medicine procurement organized by the state （hereinafter refer to as “centralized procurement list ”）. RESULTS From 2017 to 2021，415 chemical generic drugs had passed consistency evaluation in China ，including 309 varieties，1 822 specifications， 6 dosage forms ，and 17 pharmacological mechanisms ，basically belonging to 30 provinces，and 492 drug manufacturers （except 12 products had not been found the manufacturers ）；the proportion of GMPCE in essential medicine list increased from 0.96％ in 2012 edition to 25.40％ in 2018 edition；that of GMPCE in medical insurance list increased f rom 2.13％ in 2017 edition to 11.68％ in 2021 edition；in the first 5 batches of centralized procurement list，GMPCE accounted for 81.65％，and the maximum price drop after entering the list was 97.52％. CONCLUSIONS The policy linkage has been achieved with the continual increase of the number of GMPCE and their total amount in three lists in China. The accessibility and affordability of related medicines have been improved with the apparent decrease of the price of those medicines. H owever，total number of GMPCE is a little small，with the higher repetition rate of variety and the low proportion in the three lists ；the guarantee measures of those medicine supply need to be strengthened.
